identifying risk factors for thrombosis in mpns and treatment strategies
Published 6 years ago • 355 plays • Length 4:18Download video MP4
Download video MP3
Similar videos
-
2:45
an insight into clinical risk factors for progression in mpns
-
4:02
mpns and thrombosis: reducing the risk
-
1:05
hematological predictors of thrombotic risk or disease progression in essential thrombocythemia
-
2:18
molecular profiling and risk classification of patients with mpns and splanchnic vein thromboses
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial
-
2:13
current and emerging treatment options for patients with mf who are ineligible for ruxolitinib
-
1:31
risk-adjusted safety analysis of pacritinib for patients with mf
-
2:08
identifying predictors for ruxolitinib treatment-related thrombocytopenia in patients with mf
-
1:34
are thrombotic risk and progression in et predictable?
-
0:46
factors associated with progression to myelofibrosis in patients with essential thrombocythemia
-
4:25
the challenges with accurately diagnosing and risk-stratifying patients with mds
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
4:55
sysmex: early detection of essential thrombocythaemia reduces the risk of stroke in a clinic patient
-
1:36
identification of high-risk disease using molecular profiling by mymap
-
0:42
diagnostic markers to catch thrombosis early in pnh
-
19:33
patient and disease related risk factors for thrombosis
-
1:11
personalized risk assessment for transplantation in primary immunodeficiency disorders
-
1:44
predicting thrombocytopenia as a result of ruxolitinib treatment in mf
-
1:27
current diagnostic modalities for the identification of ptld